Navigation Links
Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Date:11/11/2008

12,859,000, as of December 31, 2007.

About Nventa Biopharmaceuticals Corporation:

Nventa is developing innovative therapeutics incorporating our proprietary CoVal(TM) fusion technology for the treatment of viral infections and cancers, with a focus on diseases caused by the human papillomavirus (HPV); and a Toll- like Receptor 3 (TLR3) agonist for use as a vaccine adjuvant and as an immunotherapeutic for viral infections and cancer. The company is publicly traded on the Toronto Stock Exchange under the symbol "NVN". For more information about Nventa Biopharmaceuticals Corporation, please visit the company's website located at http://www.nventacorp.com.

The audit committee of the company has reviewed and approved of the contents of this press release. Summary financial statements are attached below. The full financial statements and MD&A for the three and nine months ended September 30, 2008 can be found on SEDAR at http://www.sedar.com.

This press release contains statements which may constitute forward- looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include financial and other projections as well as statements regarding the company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only expectations, and that the company's actual future results or perform
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Crystal Diagnostics (CDx) Xpress System, ... has received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing ... collectively referred to as STEC or the “Big-6”) as well ... unit (cfu) per 325 g of raw ground beef and ...
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... the leading,management consulting firm specializing in the pharmaceutical ... practice,will be taking a leadership role at the ... by the Center for Business Intelligence,(CBI). The conference ... Crown Plaza,Valley Forge in King of Prussia, Pennsylvania. ...
... (Nasdaq:,CPHD) will present at the William Blair & ... at 10:40 a.m. ET at the New York ... Financial Officer and Dr.,David Persing, Cepheid,s Chief Medical ... The webcast, along with accompanying presentation slides, may ...
... The Netherlands and LONDON, September 26 ,Nobilon International ... business,unit of Akzo Nobel, and Protherics PLC, the ... today announced that Nobilon,has licensed Protherics, CoVaccine HT(TM) ... influenza vaccines in elderly people. More than ...
Cached Biology Technology:Campbell Alliance Managed Markets Practice to Take Leadership Role at CBI's Formulary and Reimbursement Conference 2Campbell Alliance Managed Markets Practice to Take Leadership Role at CBI's Formulary and Reimbursement Conference 3Cepheid to Present at William Blair Small-Cap Growth Stock Conference 2Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications 2Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications 3
(Date:1/22/2015)... NXTD and NXTDW) a biometric authentication company focused on ... Wocket™ smart wallet at CES 2015 in Las Vegas ... the "11 Hot Products at CES" in a review published in Wired.com, ... Newseveryday.com and "The top 10 gadgets from CES 2015" by Danny ...
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... in biomechanics and physiology from six universities, led ... of Technologys Media Lab, refute scientific claims that ... South African bilateral amputee track athlete, provide him ... Their conclusions were based on data collected at ...
... has long been a concern for environmental scientists and ... excessive reactive nitrogen in the environment is little-known beyond ... the element cycles through the environment and negatively alters ... Two new papers by leading environmental scientists bring ...
... NY) Contrary to long-held assumptions, high-salt diets ... to investigators from the Albert Einstein College of ... after examining dietary intake among a nationally representative ... researchers actually observed a significantly increased risk of ...
Cached Biology News:Breaking news: Study revives Olympic prospects for amputee sprinter 2Breaking news: Study revives Olympic prospects for amputee sprinter 3Addressing the 'nitrogen cascade' 2Addressing the 'nitrogen cascade' 3New study casts further doubt on risk of death from higher salt intake 2